If you have questions, please call us for more information about clinical trials or use our online form.
- Cancer clinical trials: 414-805-8900
- Noncancer clinical trials: 414-955-8555
Learn more about clinical trials basics and early-phase clinical trials, as well as some of the unique features our research program, including our Translational Research Unit. Froedtert & MCW health network is also part of the National Institutes of Health All of Us Research Program.
Displaying 201 - 210 of 292
An Open-Label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-Tumor Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Subjects with Unresectable, Advanced and or Metastatic Solid Tumors That Are Positive for
Objective
A Study of NT-175 in Adult Subjects With Unresectable, Advanced, and/​or Metastatic Solid Tumors That Are Positive for HLA-A*02:01 and the TP53 R175H Mutation
Protocol No
NEOGENE-NT-175-201
Randomized Phase II/III Trial of Sentinel Lymph Node Biopsy Versus Elective Neck Dissection for Early-Stage Oral Cavity Cancer
Objective
Comparing Sentinel Lymph Node (SLN) Biopsy with Standard Neck Dissection for patients with early-stage oral cavity cancer.
Protocol No
NRG-HN006
Categories
A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzumab Ozogamicin (a Conjugated Anti-CD22 Monoclonal Antibody) to Frontline Therapy in Young Adults (Ages 18-39 Years) with Newly Diagnosed Precursor B-Cell ALL
Objective
Inotuzumab Ozogamicin and Frontline Chemotherapy in Treating Young Adults With Newly Diagnosed B Acute Lymphoblastic Leukemia
Protocol No
ALLIANCE-A041501-ALL
Categories
A Phase 3, Double-Blind, Randomized, Vehicle-Controlled, Efficacy and Safety Study of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa
Objective
Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Hidradenitis Suppurativa (TRuE-HS2)
Protocol No
DERM-INCYTE-INCB018424-325
Categories
A Phase 1, Open-label Study to Evaluate the Safety and Clinical Activity of Azercabtagene Zapreleucel in Participants with B-cell Mediated Autoimmune Disorders
Objective
Azercabtagene Zapreleucel in B-cell Mediated Autoimmune Disorders
Protocol No
NEURO-TG-AZERCEL-101
Standardizing Treatments for Pulmonary Exacerbations: A Platform for Evaluating Treatment Decisions to Improve Outcomes (STOP360) Aminoglycoside Study (AG Study)
Objective
Standardizing Treatments for Pulmonary Exacerbations - Aminoglycoside Study (STOP360AG)
Protocol No
PULM-CFF-STOP360AG
Categories
An Open-Label, Global, Multi-Arm Study to Evaluate the Efficacy and Safety of Relacorilant in Combination with Different Treatment Regimens in Patients with Gynecological Cancers (BELLA)
Objective
Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Protocol No
CORCEPT-CORT125134-557-BELLA
Categories
Breast Cancer Clinical Validation Study to Predict Recurrence of High-Risk Early Breast Cancer Treated With Neoadjuvant Therapy Using a Bespoke Circulating Tumor DNA Assay to Detect Molecular Residual Disease
Objective
Study of Molecular Residual Disease Detection in Breast Cancer (MRD)
Protocol No
EXACT-EXACTDNA-003-NSABP-B-64
Categories
A Phase 2/3, Multicenter, Randomized Study of Raludotatug Deruxtecan (R-DXd), a CDH6-Directed Antibody-Drug Conjugate, in Subjects with Platinum-Resistant, High-Grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
Objective
This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer. This study will focus on R-DXd in participants with platinum-resistant, high-grade ovarian, primary peritoneal, or fallopian tube cancer.
Protocol No
GOG-3096-DAIICHI-DS6000-109
Categories
A Phase III, Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy, Safety, and Tolerability of BI 1291583 2.5 mg Administered Once Daily for up to 76 Weeks in Patients With Bronchiectasis (The AIRTIVITY Study)
Objective
The AIRTIVITY Study: A Study to Find Out Whether BI 1291583 Helps People With Bronchiectasis
Protocol No
PULM-BOEHRINGER-AIRTIVITY
Categories